By the end of last year,a group of investigators led by Professor Büller HR accomplished the global HOKUSAI-VTE trial which was funded by Daiichi-Sankyo.They conducted this trial to investigate whether the oral f...By the end of last year,a group of investigators led by Professor Büller HR accomplished the global HOKUSAI-VTE trial which was funded by Daiichi-Sankyo.They conducted this trial to investigate whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism.Edoxaban is a newly developed oral factor Xa direct inhibitor with展开更多
文摘By the end of last year,a group of investigators led by Professor Büller HR accomplished the global HOKUSAI-VTE trial which was funded by Daiichi-Sankyo.They conducted this trial to investigate whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism.Edoxaban is a newly developed oral factor Xa direct inhibitor with
